tag:blogger.com,1999:blog-6377401824680246858.post4049412535800736555..comments2024-03-05T15:49:16.751+00:00Comments on The SPC blog: Synflorix: SPC can be based on covalently bound active ingredient -- in principle ...roberthttp://www.blogger.com/profile/03575489215896576032noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-6377401824680246858.post-51099427732564849462015-01-22T19:18:57.264+00:002015-01-22T19:18:57.264+00:00The judgment leaves me unconvinced about whether a...The judgment leaves me unconvinced about whether a distinction between<br /><br />(i) a Glaxosmithkline Biologicals-type of scenarios involving an enhancement adjuvant; and<br /><br />(ii) a Question 2(b)-type scenario under Forsgren <br /><br />is the right way to go.<br /><br />I must look into this judgment in more detail, anyway. It is indeed difficult to read, particularly the last question.<br /><br />Cheers,<br /><br />A fellow in the galleys of SPC litigationAnonymousnoreply@blogger.comtag:blogger.com,1999:blog-6377401824680246858.post-37080308321745244492015-01-19T12:10:52.894+00:002015-01-19T12:10:52.894+00:00Can anyone explain to me how the CJEU reached its ...Can anyone explain to me how the CJEU reached its conclusion in the final sentence of paragraph 35?<br /><br />As far as I can see, the conclusion most definitely does NOT follow as a logical consequence of the points that the CJEU makes prior to that conclusion. Anonymousnoreply@blogger.com